Hormone Replacement Therapy: Making Informed Decisions

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

PHILADELPHIA--The Board of Directors of the National Comprehensive Cancer Network (NCCN) has elected Robert C. Young, MD, to the position of Chairman of the Board. Dr. Young, currently president of the Fox Chase Cancer Center, is internationally known for his work in the treatment of lymphoma and ovarian cancer.

PHILADELPHIA--The Board of Directors of the National Comprehensive CancerNetwork (NCCN) has elected Robert C. Young, MD, to the position of Chairmanof the Board. Dr. Young, currently president of the Fox Chase Cancer Center,is internationally known for his work in the treatment of lymphoma andovarian cancer.

Earlier this year, William T. McGivney, PhD, was named chief executiveofficer of the alliance. He joins NCCN from Aetna Health Plans where hewas vice president, Clinical and Coverage Policy.

Fred Hutchinson Cancer Research Ctr
Stanford University Medical Center
City of Hope National Medical Center
University of Nebraska Medical Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University of Michigan Comprehensive Cancer Center
Fox Chase Cancer Center
The Johns Hopkins Oncology Center
Memorial Sloan-Kettering Cancer Ctr
Northwestern U/Lurie Cancer Center
Arthur G. James Cancer Hospital &
Research Institute, Ohio State University
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
UAB (University of Alabama at Birming- ham) Comprehensive Cancer Center

Recent Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.